**Supplementary Table 1: AGREE II Assessment**

|  |  |  |
| --- | --- | --- |
| **Criterion** | **Median Rating (IQR)** | **ICC, 95% CI** |
| **Domain 1: Scope and Purpose** |  |  |
| The overall objective(s) of the guideline is (are) specifically described | 6 (6 – 6) | 0.11 (-0.94 – 0.59) |
| The health question(s) covered by the guideline is (are) specifically described | 6 (5 – 6) | -0.17 (-0.97 – 0.37) |
| The population (patients, public, etc.) to whom the guideline is meant to apply  is specifically described | 6 (5 – 7) | 0.14 (-0.75 – 0.59) |
|  |  |  |
| **Domain 2: Stakeholder Involvement** |  |  |
| The guideline development group includes individuals from all relevant  professional groups | 5 (3 – 7) | 0.69 (0.33 – 0.85) |
| The views and preferences of the target population (patients, public, etc.) have  been sought | 2 (1 – 3) | 0.46 (-0.17 – 0.75) |
| The target users of the guideline are clearly defined | 6 (4 – 7) | 0.48 (-0.12 – 0.76) |
|  |  |  |
| **Domain 3: Rigor of Development** |  |  |
| Systematic methods were used to search for evidence | 5 (2 – 7) | 0.88 (0.76 – 0.95) |
| The criteria for selecting the evidence are clearly described | 3.5 (2 – 6) | 0.82 (0.61 – 0.91) |
| The strengths and limitations of the body of evidence are clearly described | 5 (3 – 7) | 0.31 (-0.22 – 0.64) |
| The methods for formulating the recommendations are clearly described | 3 (2 – 6) | 0.88 (0.75 – 0.95) |
| The health benefits, side effects, and risks have been considered in  formulating the recommendations | 6 (4 – 7) | 0.26 (-0.21 – 0.60) |
| There is an explicit link between the recommendations and the supporting  evidence | 6 (5 – 7) | 0.55 (0.09 – 0.79) |
| The guideline has been externally reviewed by experts prior to its publication | 5 (2 – 6) | 0.67 (0.29 – 0.85) |
| A procedure for updating the guideline is provided | 2 (2 – 5) | 0.65 (0.26 – 0.84) |
|  |  |  |
| **Domain 4: Clarity of Presentation** |  |  |
| The recommendations are specific and unambiguous | 6 (5 – 7) | -0.14 (-0.61 – 0.30) |
| The different options for management of the condition or health issue are  clearly presented | 6 (5 – 7) | 0.11 (-0.13 – 0.40) |
| Key recommendations are easily identifiable | 6 (6 – 7) | -0.10 (-0.84 – 0.41) |
|  |  |  |
| **Domain 5: Applicability** |  |  |
| The guideline describes facilitators and barriers to its application | 3 (2 – 5) | 0.48 (-0.05 – 0.75) |
| The guideline provides advice and/or tools on how the recommendations can  be put into practice | 5 (3 – 6) | 0.06 (-0.33 – 0.42) |
| The potential resource implications of applying the recommendations have  been considered | 5 (3 – 6) | 0.51 (0.25 – 0.77) |
| The guideline presents monitoring and/or auditing criteria | 3 (2 – 5) | 0.18 (-0.78 – 0.62) |
|  |  |  |
| **Domain 6: Editorial Independence** |  |  |
| The views of the funding body have not influenced the content of the  guideline | 3 (2 – 6) | 0.62 (0.21 – 0.82) |
| Competing interests of guideline development group members have been  recorded and addressed | 5 (2 – 6) | 0.77 (0.51 – 0.89) |
|  |  |  |
| **Overall Guideline Assessment** | 5 (3 – 6) | 0.80 (0.57 – 0.91) |